

Published on European Association of Hospital Pharmacists (https://www.eahp.eu)

Home > HP Practice > EAHP COVID-19 Resource Centre > EAHP COVID-19 Resource Centre | European bodies



European Medicines Agency

- **Dedicated webpage on COVID-19** [1] EMA has put together a dedicated website which summarized information on COVID-19.
- \bullet EMA Communication: Reporting suspected side effects of medicines in patients with COVID-19 $_{\rm [2]}$

EMA and the national competent authorities are reminding healthcare professionals and patients with confirmed or suspected coronavirus disease (COVID-19) to report suspected side effects that they experience with any of the medicines they are taking.

European Directorate for the Quality of Medicines & HealthCare (EDQM)

- Information on licensed products as well as extemporaneous preparations which may be suitable for treatment of paediatric patients with COVID-19 [3]

 The European Paediatric Formulary Working Party at the EDQM compiled existing knowledge on paediatric formulations for active substances which are under investigation for the treatment of COVID-19 as well as known authorised medicinal products. This information might also be useful for other patient groups. Information on Chloroquine, Hydroxychloroquine and Lopinavir/Ritonavir is currently available.
- EDQM's contributions to the protection of public health in the COVID-19 pandemic: latest information [4]
 - EDQM shared information on the preparedness of the Directorate as well as on information that has been made available to address the COVID-19 pandemic.

The disclaimer for the EAHP COVID-19 Resource Centre can be found here [5]

Last update: 17 November 2020

Links

- [1] https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19
- [2] https://www.ema.europa.eu/en/news/reporting-suspected-side-effects-medicines-patients-covid-19
- [3] https://www.edqm.eu/en/news/products-and-extemporaneous-preparation-paediatric-formulations-may-be-useful-treatment-covid

- $[4] \ https://www.edqm.eu/en/edqms-contributions-protection-public-health-covid-19-pandemic-latest-information \#Pharmacopoeia \%20 and \%20 quality \%20 standards$
- [5] https://www.eahp.eu/hp-practice/hospital-pharmacy/eahp-covid-19-resource-centre